---
document_datetime: 2023-09-21 20:24:09
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/conbriza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: conbriza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.395033
conversion_datetime: 2025-12-23 01:48:05.62592
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EMA/172882/2021

## Conbriza

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0055               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/03/2021                          |                                             | PL                               |           |
| IB/0053              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 11/12/2020                          |                                             | SmPC, Annex II, Labelling        |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                                                                                                                               |            |            | and PL                 |                                   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/302/2 01910 | Periodic Safety Update EU Single assessment - bazedoxifene                                                                                                                                                                                                                                                                                                    | 11/06/2020 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0050            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 02/12/2019 |            | PL                     |                                   |
| N/0049            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 09/04/2019 |            | PL                     |                                   |
| N/0048            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 24/10/2018 |            | PL                     |                                   |
| T/0047            | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                           | 11/07/2018 | 02/08/2018 | SmPC, Labelling and PL |                                   |
| IA/0046/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites | 23/05/2018 | n/a        |                        |                                   |
| N/0045            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 02/05/2018 | 02/08/2018 | Labelling              |                                   |
| PSUSA/302/2 01610 | Periodic Safety Update EU Single assessment - bazedoxifene                                                                                                                                                                                                                                                                                                    | 05/05/2017 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0043           | B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                | 26/01/2017   | n/a        |             |                                                                                                                                          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0042           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                         | 14/12/2016   | n/a        |             |                                                                                                                                          |
| N/0041            | Update of the package leaflet with revised contact details of the local representatives for France, Germany, Italy and Spain. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                       | 28/10/2016   | 02/08/2018 | PL          |                                                                                                                                          |
| PSUSA/302/2 01510 | Periodic Safety Update EU Single assessment - bazedoxifene                                                                                                                                                                                                                                                                                                                           | 26/05/2016   | 22/07/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/302/201510. |
| IB/0039/G         | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 08/02/2016   | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0038           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                            | 24/09/2015   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0037            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                          | 24/06/2015   | 26/05/2016 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0036           | Update of section 4.8 of the SmPC in order to update ADRs frequency categories to align with the Company Core Data Sheet. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder took the opportunity to make minor editorial changes to section 4.2 of the SmPC to bring it in line with the latest QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/05/2015   | 26/05/2016 | SmPC and PL           | Based on the review of frequency analyses of the already labelled ADRs, frequencies of the ADRs retinal vein thrombosis (change from 'rare' to 'uncommon'), oedema peripheral ('common' to 'very common'), rash ('frequency unknown' to 'common'), and pruritus ('frequency unknown' to 'common') have been changed in SPC section 4.8 and PL section 4 has been amended accordingly. |
| PSUSA/302/2 01410 | Periodic Safety Update EU Single assessment - bazedoxifene                                                                                                                                                                                                                                                                                                                                                                                                                | 07/05/2015   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                     |
| PSUV/0034         | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/05/2014   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                     |
| R/0032            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/12/2013   | 17/02/2014 | SmPC, Annex II and PL | Based on the CHMP review of data on quality, safety and efficacy, including all variations introduced since the granting of the initial marketing authorisation, the CHMP considered that the benefit-risk balance of Conbriza in the                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                |            |            |      | authorised indications remains favourable and therefore recommended the renewal of the marketing authorisation, subject to the conditions as laid down in Annex II to the Opinion. The CHMP considered that the Marketing Authorisation could be granted with unlimited validity. The CHMP recommended amendments to the Annexes I, II and IIIB. These changes do not affect the benefit-risk balance of the product, which remains positive.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 18/12/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0031   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                    | 22/05/2013 | 14/08/2013 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0030   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                  | 22/02/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0235/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV               | 06/12/2012 | n/a        |      | C.I.z - To replace the Detailed Description of the Pharmacovigilance System (DDPS) with the Pharmacovigilance System Master File (PSMF).                                                                                                                                                                                                                                                                                                        |
| IB/0027   | B.I.a.2.e - Changes in the manufacturing process of                                                                                                                                                                                                                                            | 30/11/2012 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------|
| IB/0026   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                       | 30/11/2012 | n/a        |                                                                 |
| IA/0028   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                                                                                                                        | 14/11/2012 | n/a        |                                                                 |
| A20/0025  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the opinion of the CHMP further to the concerns raised during a Good Clinical Practice inspection on the conduct of bio-analytical studies by the Cetero Research facilities (Houston, USA), to assess the impact thereof on the risk-benefit balance of Conbriza and to give its opinion whether the marketing authorisation of this product should be maintained, varied, suspended or withdrawn. | 19/07/2012 | 01/10/2012 | Please refer to the assessment report : EMEA/H/C/913/A- 20/0025 |
| IB/0023/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary                                                                                                                                                                                                                                               | 25/07/2012 | n/a        |                                                                 |

<div style=\"page-break-after: always\"></div>

|           | packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0169/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 08/06/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0022   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                  | 29/05/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0021   | This type II variation concerns an update of SmPC sections 4.4, 4.8 and 5.1 with relevant safety and efficacy data obtained following 7 years of treatment with bazedoxifene in extension II to Study 3068A1- 301-WW. In addition, upon request by the CHMP following the assessment of PSUR 4, the MAH proposes the addition of wording in section 5.1 of the SmPC to include the incidences of thyroid cancer and                                                                                  | 19/04/2012 | 25/05/2012 | SmPC, Annex II, Labelling and PL | The efficacy and safety data supporting the marketing authorisation for bazedoxifene were based on the multicentre, double-blind, randomized, placebo and raloxifene controlled, Phase 3 study 3068A1-300 GL in postmenopausal women for the prevention of osteoporosis and the 36 month, multicentre, double-blind, randomized, placebo and raloxifene controlled, Phase 3 study 3068A1- 301 WW in older, postmenopausal women for the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| ovarian cancer observed in Study 3068A1-301-WW, and the update of sections 4.7 and 4.8 of the SmPC to include information on the ocular adverse events reported and advice regarding the effects of these events on the ability to drive. The Package Leaflet has been updated accordingly. Furthermore, the MAH has taken the opportunity to update the annexes in line with the latest QRD template, version 8, and to update the list of local representatives in the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- data   | clinical, clinical or pharmacovigilance   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|

<div style=\"page-break-after: always\"></div>

| placebo (1.78) groups.  The rate per 1,000 women years  for TIA was higher for the bazedoxifene 20 mg group  (0.96) compared to placebo (0.55).  With reference to effects on the uterus, after 7 years of  treatment, the endometrial thickness in the bazedoxifene  20 mg group did not change and remained similar to  placebo; there were no cases of endometrial cancer in the  bazedoxifene 20 mg group compared to 7 cases in the  placebo group (p&lt;0.008).  In the osteoporosis treatment study in 7,492  postmenopausal women (mean age, 66 years), among  1,886 subjects treated with bazedoxifene (20 mg), there  were 5 cases of thyroid cancer (0.69 per 1,000) and among  1,885 subjects treated with placebo, there was 1 case of  thyroid cancer (0.14 per 1,000) after 7 years of treatment.  There were no cases of thyroid cancer in the 40 mg  treatment group up to 5 years. Further, there were 5 cases  of ovarian cancer (0.69 per 1,000) and among 1,885  subjects treated with placebo, there were 0 cases of  ovarian cancer after 7 years of treatment.  There was one  case of ovarian cancer in the 40 mg treatment group up to  5 years. After 7 years of treatment, there were 13 cases of  breast cancer in the bazedoxifene 20 mg group (1.78 per  1,000 women-years) and 11 cases in the placebo group  (1.50 per 1,000 women-years).  There have been post-marketing reports of ocular events other than retinal vein thrombosis.  These reports include visual acuity reduced, blurred vision, photopsia, visual field defect, visual impairment, dry eye, eyelid oedema, blepharospasm, eye pain and eye swelling.  The underlying nature of these events is uncertain.  If ocular symptoms occur, patients should be advised to seek medical attention   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | and should avoid driving or use of machines that requires accurate visual perception until symptoms have resolved, or until they have received medical advice that it safe to do so.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 21/07/2011 | n/a |                                                                                                                                                                                        |
| IB/0018/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                                                                                           | 08/07/2011 | n/a |                                                                                                                                                                                        |
| IA/0019/G | This was an application for a group of variations. B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                                                 | 28/06/2011 | n/a |                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | - Change in the specification parameters limits of the immediate packaging of the AS - of a non-significant specification parameter deletion of an obsolete parameter)                                                                                                                              |            |            |                 | B.I.c.2.c and/or Deletion (e.g.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0015/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of | 14/06/2011 | n/a        |                 | specification limits              |
| IA/0016   | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                        | 12/05/2011 | n/a        |                 |                                   |
| WS/0117   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH        | 14/04/2011 | 14/04/2011 |                 |                                   |
| IA/0014   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for                                                                                                                                                                                                 | 12/04/2011 | n/a        | Annex II and PL | batch release                     |
| IA/0013   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                       | 11/03/2011 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010   | Update of Summary of Product Characteristics, Annex II and Package Leaflet. Please refer to the scientific discussion \"Conbriza/H/C/000913/II/10\". C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                       | 20/01/2011 | 21/02/2011 | SmPC, Annex II and PL  | This type II variation concerns an update of sections 4.2, 4.4, 4.8 and 5.1 of the SPC to add safety and efficacy information after long-term treatment for up to 5-years from an extension of the pivotal Study 301-WW. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update Annex II with the standard DDPS wording, to update the annexes in line with the current QRD template, version 7.3.1 and the Guideline on Summary of Product Characteristics, revision 2, and to update the list of local representatives in the Package Leaflet. |
| T/0012    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                             | 29/11/2010 | 20/12/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0011   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                             | 02/12/2010 | 02/11/2010 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0008/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the | 23/04/2010 | n/a        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |     |    | major contractual arrangements   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|----------------------------------|
| N/0009  | Update of 7 local Pfizer representatives in the package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                              | 22/04/2010 | n/a | PL |                                  |
| IB/0007 | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                                                                                  | 05/02/2010 | n/a |    |                                  |
| IA/0006 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                               | 17/11/2009 | n/a |    |                                  |
| IA/0005 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                           | 13/10/2009 | n/a |    |                                  |
| IA/0004 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                           | 13/10/2009 | n/a |    |                                  |
| IA/0003 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                               | 11/09/2009 | n/a |    |                                  |

<div style=\"page-break-after: always\"></div>

| IA/0002   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 11/09/2009   | n/a   |
|-----------|--------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0001   | IA_13_a_Change in test proc. for active substance - minor change                                 | 14/08/2009   | n/a   |